Kerntke Otto McGlone Wealth Management Group’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-7,713
Closed -$869K 38
2021
Q2
$869K Buy
7,713
+95
+1% +$10.7K 0.35% 48
2021
Q1
$824K Sell
7,618
-192
-2% -$20.5K 0.43% 49
2020
Q4
$837K Buy
7,810
+120
+2% +$11.5K 0.49% 48
2020
Q3
$674K Buy
7,690
+6
+0.1% +$565 0.49% 51
2020
Q2
$754K Buy
7,684
+131
+2% +$11.5K 0.69% 41
2020
Q1
$575K Buy
7,553
+72
+1% +$6.13K 0.64% 42
2019
Q4
$662K Buy
+7,481
New +$621K 0.56% 51

Other funds holding ABBV

Kerntke Otto McGlone Wealth Management Group's ABBV Position: Q3 2021 in Review

Kerntke Otto McGlone Wealth Management Group sold out of AbbVie (ABBV) in Q3 2021, closing a stake of 7,713 shares — an estimated $869K sold.

Kerntke Otto McGlone Wealth Management Group first reported a position in ABBV in Q4 2019 and held it in 7 quarters. The position peaked at $869K in Q2 2021. 2,654 funds tracked by Wall St. Rank hold ABBV as of Q3 2021.

  • Kerntke Otto McGlone Wealth Management Group reported no remaining AbbVie position as of Q3 2021 after selling out during the quarter.
  • Kerntke Otto McGlone Wealth Management Group sold 7,713 AbbVie shares in Q3 2021, an estimated $869K.
  • Kerntke Otto McGlone Wealth Management Group first reported a position in AbbVie in Q4 2019 and held it in 7 quarters.
  • Kerntke Otto McGlone Wealth Management Group's AbbVie position peaked at $869K in Q2 2021.
  • 2,654 funds tracked by Wall St. Rank held AbbVie as of Q3 2021.

Based on Kerntke Otto McGlone Wealth Management Group's 13F filing for Q3 2021, filed 9 Nov 2021.